Dr. Louis Adrian Vandermolen, MD

Dr. Vandermolen practices at Keck Medicine of USC - USC Norris Oncology/Hematology Newport Beach - Oncology, Hematology, Cancer Therapy, Blood Disorders - HOPD in Newport Beach, California.

Dr. Vandermolen's NPI, 1568540193, was assigned on November 1, 2006. Dr. Vandermolen graduated from Loyola University Chicago Stritch School of Medicine in 1980. Dr. Vandermolen's California license number on file is G51429.

Dr. Vandermolen's primary practice is Keck Medicine of USC - USC Norris Oncology/Hematology Newport Beach - Oncology, Hematology, Cancer Therapy, Blood Disorders - HOPD, at 330 Old Newport Blvd, Newport Beach, CA 92663.

Dr. Vandermolen's primary practice is Keck Medicine of USC - USC Norris Oncology/Hematology Newport Beach - Oncology, Hematology, Cancer Therapy, Blood Disorders - HOPD in Newport Beach, California. Dr. Vandermolen is also affiliated with Hoag Hospital Newport Beach. The medical group on file is USC Care Medical Group. Dmand AI also links Dr. Vandermolen to 1 more hospital, 1 group practice or clinic, 1 home health agency and 1 other site, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Vandermolen practices, 6 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Vandermolen's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Vandermolen is board certified in internal medicine by the American Board of Internal Medicine. Dmand AI has Dr. Vandermolen's licenses on file in 5 states: California, Arkansas, Maryland, Tennessee and Texas.

Dmand AI lists breast cancer, chronic anemia, chronic embolism thrombosis, chronic leukemia, colorectal cancer, immune deficiency disease, lung cancer and lymphoma among the conditions Dr. Vandermolen treats.

CMS data shows 7,602 Medicare services from Dr. Vandermolen across 10 procedure codes in 2024, for 1,503 Medicare patients. Medicare paid $442,858 for them.

CMS counts 1,503 Medicare patients who saw Dr. Vandermolen in 2024. The largest group is 75 to 84, with 694 patients. 75% of them have cancer, and 75% have high cholesterol. 2% are also on Medicaid. Their average risk score is 1.51, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Vandermolen's median patient age at 76, with 80% women.

In 2024, Dr. Vandermolen wrote 2,712 Medicare Part D claims for 552 patients. 83% of them were for generic drugs. CMS names the drug for 2,369 of them, across 44 drugs with 11 or more claims each, at $3,570,541 in total drug cost. In 2023, CMS named 2,351 claims across 44 drugs.

Dr. Vandermolen accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Vandermolen as offering telehealth.

Dmand AI links 32 papers to Dr. Vandermolen, published from 2011 to 2024. 2011 was the busiest year, with 3. The most frequent topics are Interleukin-2, Recombinant Proteins and Kidney Neoplasms. Dr. Vandermolen has published most often in Cancer Biother Radiopharm. Dr. Vandermolen's most frequent co-authors are Robert O. Dillman, MD, FACP, Khosrow Mahdavi, MD and Jeffrey William Clark, MD.

CMS Open Payments shows 19 general payments to Dr. Vandermolen from 9 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 80% of the total. AstraZeneca Pharmaceuticals LP paid the most, $527.

Dmand AI lists 1 award for Dr. Vandermolen.

Dr. Vandermolen graduated from Loyola University Chicago Stritch School of Medicine in 1980.

Dr. Vandermolen is in network with 13 carriers, including Aetna, Blue Cross Blue Shield of Michigan and United Healthcare. PPO plans come from the most carriers, 8. Check the plan with the practice before a visit.